• Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis
• Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%
• Income from operations increased 18%; non-GAAP income from operations up 19%

Resmed Inc. announced results for its second quarter of fiscal year 2026. Revenue grew 11% to $1.4 billion, or 9% on a constant currency basis, driven by increased demand for Resmed's portfolio of sleep devices, masks, and accessories. Gross margin expanded by 320 basis points to 61.8%, and non-GAAP gross margin increased by 310 basis points to 62.3%, primarily due to manufacturing and logistics efficiencies as well as component cost improvements. Income from operations rose 18%, and non-GAAP income from operations increased 19%. Net income for the quarter was $393 million, and diluted earnings per share was $2.68. Non-GAAP net income grew 15% to $411 million, and non-GAAP diluted earnings per share increased 16% to $2.81, driven by strong sales growth and gross margin improvement. Operating cash flow for the quarter was $340 million. During the quarter, Resmed paid $88 million in dividends and repurchased 704,000 shares for $175 million. The company highlighted key business and operational highlights, including new research demonstrating the benefits of positive airway pressure therapy, FDA clearance for an AI-enabled digital medical device, and a presentation at the J.P. Morgan Healthcare Conference.

Resmed provided the following forward-looking financial guidance for fiscal year 2026: revenue growth of 9-11% on a constant currency basis, non-GAAP gross margin expansion of 300-320 basis points, and non-GAAP EPS growth of 15-17%.

Resmed expects to continue investing in innovation to scale its digital health capabilities and expand global access to life-saving care, while delivering sustainable, profitable growth.